If you think any of the remarks in the conference call yesterday were anything but unbridled enthusiasm for what all three speakers consider unblemished and completely positive results... then you really have a serious problem with comprehension.
Reality time: three trials starting before year’s end. Phase 2/3 start in AD will cause huge surge in pps before 12/31/17. That’s the breaks ladies and gentlemen.
Complete confirmation yesterday that all of the company’s planned and stated goals for this year are still on track, completely paid for by current cash holdings of AVXL, and results/patients in 2a trial are CONTINUING TO IMPROVE even now.
AGD2, I think yesterday's presentation was, in a sense, preparing us for how the CTAD presentation will be structured and it will contain several more slides/graphs that will demonstrate how dose optimization has moved more patients in the the upper right corner at a fast rate, i.e., either after 6/18 or 9/21 months of the new/initial trial, most are there.
On the 4th, we might have that action word often used cartoons ...